Literature DB >> 29624655

Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.

Alyson V Ridpath1, Polina V Rzepka2, Sabrina M Shearer2, Scott R Scrape3, Thomas E Olencki4, Benjamin H Kaffenberger2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29624655     DOI： 10.1111/ijd.13970

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  8 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.

Authors:  O F Khan; J Monzon
Journal:  Curr Oncol       Date:  2020-04-01       Impact factor: 3.677

Review 3.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

Review 4.  Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.

Authors:  Rikke Bech; Line Kibsgaard; Christian Vestergaard
Journal:  Front Med (Lausanne)       Date:  2018-09-04

5.  Combination Therapy of Plasma Exchange and Rituximab to Treat Cicatricial Pemphigoid and Bullous Pemphigoid.

Authors:  Anuj Kunadia; Naveed Sami
Journal:  Cureus       Date:  2021-11-27

6.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

Review 7.  Off-Label Uses of Rituximab in Dermatology.

Authors:  Connor Cole; Kyle T Amber
Journal:  Curr Dermatol Rep       Date:  2022-10-06

8.  Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.

Authors:  Dennis Niebel; Dagmar Wilsmann-Theis; Thomas Bieber; Mark Berneburg; Joerg Wenzel; Christine Braegelmann
Journal:  Dermatopathology (Basel)       Date:  2022-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.